Literature DB >> 7929824

Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans.

J E Nestler1, Z Kahwash.   

Abstract

To test the hypothesis that insulin acutely enhances the metabolic clearance rate (MCR) of dehydroepiandrosterone in humans, the effect of a short-term insulin infusion on the MCR of dehydroepiandrosterone was assessed in 10 men and 7 women. After an overnight fast, dehydroepiandrosterone was infused at 3.47 mumol/h for 6.5 h. At 240 min, a hyperinsulinemic-euglycemic clamp was begun by infusing insulin at 21.5 pmol/kg per min for 2.5 h. MCR of dehydroepiandrosterone was calculated at baseline (210-240 min) and during the insulin infusion (360-390 min). A control study was conducted at least 1 wk later, in which 0.45% saline was substituted for the hyperinsulinemic-euglycemic clamp. During the insulin clamp study, serum insulin rose from 34 +/- 2 to 1084 +/- 136 pmol/liter (P = 0.0001) in men and from 40 +/- 5 to 1357 +/- 175 pmol/liter (P = 0.0003) in women, while serum glucose remained constant in both groups. MCR of dehydroepiandrosterone rose in men during the insulin infusion from 2443 +/- 409 to 3599 +/- 500 liters/24 h (P = 0.003), but did not change during the control saline infusion. In contrast, MCR of dehydroepiandrosterone in women did not change in the insulin clamp study during insulin infusion (2526 +/- 495 liters/24 h at baseline vs. 2442 +/- 491 liters/24 h during insulin infusion; P = 0.78). These findings suggest that insulin acutely increases the MCR of dehydroepiandrosterone in men but not in women.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929824      PMCID: PMC295288          DOI: 10.1172/JCI117487

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

Review 1.  Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease.

Authors:  A N Nafziger; D M Herrington; T L Bush
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

2.  The secretion of dehydroepiandrosterone and dehydroepiandrosterone sulphate in man.

Authors:  E Nieschlag; D L Loriaux; H J Ruder; I R Zucker; M A Kirschner; M B Lipsett
Journal:  J Endocrinol       Date:  1973-04       Impact factor: 4.286

3.  Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice.

Authors:  L L Pashko; A G Schwartz
Journal:  Diabetes       Date:  1993-08       Impact factor: 9.461

Review 4.  Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis?

Authors:  J E Nestler; J N Clore; W G Blackard
Journal:  FASEB J       Date:  1992-09       Impact factor: 5.191

5.  Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta.

Authors:  F Ishihara; K Hiramatsu; S Shigematsu; T Aizawa; A Niwa; N Takasu; T Yamada; K Matsuo
Journal:  Cardiology       Date:  1992       Impact factor: 1.869

6.  Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults.

Authors:  B Zumoff; R S Rosenfeld; G W Strain; J Levin; D K Fukushima
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

7.  Insulin inhibits adrenal 17,20-lyase activity in man.

Authors:  J E Nestler; M A McClanahan; J N Clore; W G Blackard
Journal:  J Clin Endocrinol Metab       Date:  1992-02       Impact factor: 5.958

8.  Relationship of sex hormones to lipids and lipoproteins in nondiabetic men.

Authors:  S M Haffner; L Mykkänen; R A Valdez; M S Katz
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

9.  Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus.

Authors:  E Barrett-Connor
Journal:  Ann Intern Med       Date:  1992-11-15       Impact factor: 25.391

10.  Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice.

Authors:  D L Coleman; E H Leiter; R W Schwizer
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

View more
  5 in total

Review 1.  Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome.

Authors:  E Carmina; R A Lobo
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 2.  The biological actions of dehydroepiandrosterone involves multiple receptors.

Authors:  Stephanie J Webb; Thomas E Geoghegan; Russell A Prough; Kristy K Michael Miller
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

3.  The short-term effect of dietary pectin on plasma levels and renal excretion of dehydroepiandrosterone sulfate.

Authors:  T Remer; K Pietrzik; F Manz
Journal:  Z Ernahrungswiss       Date:  1996-03

Review 4.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

5.  Can Low SHBG Serum Concentration Be A Good Early Marker Of Male Hypogonadism In Metabolic Syndrome?

Authors:  Piotr Jarecki; Waldemar A Herman; Elżbieta Pawliczak; Katarzyna Lacka
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-21       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.